Molecule News and Research

RSS

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S and ZymoGenetics, Inc. today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

From Novo Nordisk 8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

8 Dec 2009

Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

7 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

7 Dec 2009

Silicon to transport drugs in the human body: a novel drug delivery method under development

Several Finnish universities have joined forces to develop an innovative drug delivery method that utilises silicon to transport drugs in the human body. Among other advances, the project has been able to sustain the effect of peptides controlling appetite, which may facilitate the use of nanotechnology for dieting purposes. The research is being carried out as part of the Academy of Finland's Research Programme on Nanoscience (FinNano).

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

New step in the proofreading process that helps maintain accuracy of DNA replication identified

Wayne State researchers have for the first time observed the movement of a single molecule of DNA polymerase as it incorporates nucleotides one by one. More significantly, they have identified a previously unknown step that they speculate is part of the proofreading process known to prevent the polymerase from producing cancer-causing mutations.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Study on Helicos BioSciences' single molecule sequencing technology published

Helicos BioSciences Corporation today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid.

4 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

Advantages of Helicos BioSciences' single molecule sequencing technology presented

Helicos BioSciences Corporation announced today that, as previously disclosed, it has posted a presentation on its website regarding the advantages of Helicos’ single molecule sequencing technology in clinical diagnostics.

4 Dec 2009

New biochemical probe may help in identifying toxic proteins associated with Alzheimer's disease

Alzheimer's disease (AD) is one of the most heartbreaking diagnoses a person can receive. This irreversible, progressive brain disease slowly destroys memory and thinking skills and eventually even the ability to carry out the simplest tasks

4 Dec 2009

Discovery of antibiotic molecule may lead to the development of potent antibacterial drugs

An antibiotic that binds to a well-established target in a novel and unexpected way could be the inspiration for designing new, more potent antibacterial drugs.

4 Dec 2009

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the DP2 (also known as CRTH2) receptor.

3 Dec 2009

NHLBI awards new federal grant to improve the quality of stored transfusion blood

A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem.

3 Dec 2009

VARI scientists determine the structure of receptors that plants use to sense ABA

Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants respond to environmental stresses such as drought and cold.

3 Dec 2009

Exercise remains one of the most effective interventions for peripheral artery disease

Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.

3 Dec 2009

Fruit flies use same molecular mechanisms as humans for maintaining cholestrol

More importantly, according to two new studies led by a University of Utah human geneticist, fruit flies use the same molecular mechanisms as humans to help maintain proper balances of cholesterol and a key form of stored fat that contributes to obesity. The findings mean that as researchers try to learn more about the genetic and biological processes through which people regulate cholesterol and fat metabolism, the humble fruit fly, also called Drosophila, can teach humans much about themselves.

2 Dec 2009

Molecule News and Research

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Results of preclinical studies evaluating AC220 to be presented at ASH annual meeting

Synta Pharmaceuticals announces study results of elesclomol

Albert Einstein College of Medicine receives SU2C grant for cancer research

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

Silicon to transport drugs in the human body: a novel drug delivery method under development

Preclinical data of Curis' HSP 90 inhibitor published

New step in the proofreading process that helps maintain accuracy of DNA replication identified

New SPC3649 drug found effective in treating HCV infections

Study on Helicos BioSciences' single molecule sequencing technology published

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Advantages of Helicos BioSciences' single molecule sequencing technology presented

New biochemical probe may help in identifying toxic proteins associated with Alzheimer's disease

Discovery of antibiotic molecule may lead to the development of potent antibacterial drugs

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

NHLBI awards new federal grant to improve the quality of stored transfusion blood

VARI scientists determine the structure of receptors that plants use to sense ABA

Exercise remains one of the most effective interventions for peripheral artery disease

Fruit flies use same molecular mechanisms as humans for maintaining cholestrol

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News